Pixium Vision

Pixium Vision develops bionic vision systems for patients with severe vision loss. Its lead product, Prima, is a wireless sub-retinal implant system designed for Dry-ARMD. The company has completed a human feasibility study for Prima in Europe and expects to start implantations in a US feasibility study in H119.

Equities

Equities by Sector

Sectors

Megatrends

Thematics

Latest

Edison explains: Europe’s ageing buildings

Stock of the month – PZ Cussons

Q226 reflections: Leadership swings back – the value case holds

Audiovisual

Latest

The Metals Company – equity proposition

Vantage: Rockwood Strategic – UK small-cap value and active engagement

Bull, Bear & Beyond – Living REIT: executive interview

About Edison

Corporates

Investors

Careers

Pixium Vision (PAR: PIX)

Latest Insights

Pixium Vision — Safeguard proceedings underway

Pixium Vision — Shareholder loan extends runway

Pixium Vision — Focusing on reaching the PRIMAvera milestone

Pixium Vision — Breakthrough designation provides validation

Market Data

Sector

Research

Pixium Vision — Remote rehabilitation system approved

Pixium Vision — ESGO financing deal shores up balance sheet

Pixium Vision — First Prima implantation in Italy

Pixium Vision — Moving ahead as expected

Pixium Vision — PRIMAvera recruitment timing pushed out

Pixium Vision — Three-year data confirms continued Prima safety

Pixium Vision — Advancing towards sight restoration in dry-AMD

Pixium Vision – executive interview

Pixium Vision — Capital increase strengthens funding runway

Pixium Vision — Signalling an intent to access US investors

Pixium Vision — Back to basics as Second Sight deal is called off

Pixium Vision — Second Sight $28m financing adds clouds to deal

Pixium Vision — FY20 results in line, awaiting merger updates

Pixium Vision – Edison Open House interview

Pixium Vision — Pixium Vision to combine with Second Sight

Pixium Vision — ANSM approval to start PRIMAvera pivotal study

Pixium Vision — Q3 results in line, awaiting pivotal study approval

Pixium Vision — H120 results broadly in line

Pixium Vision — €7.3m capital increase completed

Pixium Vision — Restoring eyesight in advanced Dry-AMD

Pixium Vision — Prima 2 18-month data shows strong promise

Pixium Vision — Strategy in place to mitigate COVID-19 effects

Pixium Vision — Successful Prima activation in first US patient

Pixium Vision — Wrapping up 2019 with a solid financial position

Pixium Vision — US feasibility study now underway

Pixium Vision — Pixium to raise up to €10m to advance Prima

Pixium Vision — Pixium to raise up to €10m to advance Prima

Pixium Vision — Building feasibility data on way to pivotal study

Pixium Vision — Refining Prima system before starting pivotal trial

Pixium Vision — Pixium appoints new CEO

Pixium Vision — Prima gearing up for a pivotal year

Pixium Vision — Financials in line as Prima advances

Pixium Vision — Financials in line as Prima advances

Pixium Vision — Positive interim six-month Prima data

Pixium Vision — Encouraging signs in Prima EU feasibility study

Pixium Vision — H118 update reflects continued Prima progress

Pixium Vision — Focus shifts to Prima as human trials proceed

Pixium Vision — Successful Prima activation in first patient

Pixium Vision — Pixium cleared to start EU Prima feasibility study

Pixium Vision — Pixium seeks to address short Iris II lifespan

Pixium Vision — Forfait Innovation decision postponed

Pixium Vision — Key advancements for Iris II and Prima in 2017

Pixium Vision — Update 12 January 2017

Pixium Vision — Update 19 October 2016

Pixium Vision — Update 27 July 2016

Pixium Vision — Update 15 July 2016

Pixium Vision — Update 24 February 2016

Pixium Vision — Update 7 January 2016

Pixium Vision — Update 22 September 2015

Further insights

Retinal implants

Edison explains: Investing in health stocks – how policy clarity is opening doors

The CNS renaissance: Innovations are reshaping neurological therapies